Sacituzumab Govitecan (SG)+Toripalimab Clinical Trials

1 actively recruiting trial

Also known as: GS-0132, IMMU-132, Toripalimab, Trodelvy™

Filter by location:

Other1 trial

Sacituzumab Govitecan + Toripalimab as First - Line Therapy for Advanced Triple - Negative Breast Cancer and Biomarker Exploration

Trial data from ClinicalTrials.gov. Trial status and eligibility can change — verify directly with the study contact or on ClinicalTrials.gov.

This site does not provide medical advice. Always consult your doctor before considering enrollment in a clinical trial. Learn more on our About page.